Baxter International Inc  

(Public, NYSE:BAX)   Watch this stock  
Find more results for BAX
67.37
+1.04 (1.57%)
Real-time:   10:09AM EST
NYSE real-time data - Disclaimer
Currency in USD
Range 65.93 - 67.60
52 week 49.30 - 72.58
Open 66.76
Vol / Avg. 304,502.00/3.46M
Mkt cap 36.71B
P/E 51.66
Div/yield 0.16/0.95
EPS 1.30
Shares 544.83M
Beta 0.78
Inst. own 87%
May 2, 2018
Baxter International Inc Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
Apr 24, 2018
Q1 2018 Baxter International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 13, 2018
Baxter International Inc at Barclays Global Healthcare Conference - 10:15AM EDT - Add to calendar
Mar 6, 2018
Baxter International Inc at Raymond James Institutional Investors Conference - 4:35PM EST - Add to calendar
Feb 21, 2018
Baxter International Inc at RBC Capital Markets Healthcare Conference - 10:30AM EST - Add to calendar
Feb 14, 2018
Baxter International Inc at Leerink Partners Global Healthcare Conference - Webcast
Feb 1, 2018
Q4 2017 Baxter International Inc Earnings Release
Feb 1, 2018
Q4 2017 Baxter International Inc Earnings Call - Webcast
Jan 8, 2018
Baxter International Inc at JPMorgan Healthcare Conference - Webcast
Jan 8, 2018
Baxter International Inc at JPMorgan Healthcare Conference - Q&A Session
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -2.20% 6.86%
Operating margin 10.20% 11.91%
EBITD margin - 11.91%
Return on average assets - -
Return on average equity - -
Employees 48,000 -
CDP Score - A-

Address

1 Baxter Pkwy
DEERFIELD, IL 60015-4625
United States - Map
+1-847-9482000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.

Officers and directors

Jose E. Almeida Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
James K. Saccaro Corporate Vice President and Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Giuseppe Accogli Senior Vice President, President - Global Businesses
Age: 46
Bio & Compensation  - Reuters
Brik V. Eyre Senior Vice President, President - Americas
Age: 53
Bio & Compensation  - Reuters
Marcus Schabacker M.D. Ph.D. Chief Scientific Officer, Corporate Vice President
Age: 53
Bio & Compensation  - Reuters
Scott Pleau Corporate Vice President - Operations
Age: 51
Bio & Compensation  - Reuters
Sean Martin Corporate Vice President, General Counsel
Bio & Compensation  - Reuters
Jeanne K. Mason Ph.D. Corporate Vice President - Human Resources
Age: 61
Bio & Compensation  - Reuters
Paul Vibert Corporate Vice President, President - International
Age: 57
Bio & Compensation  - Reuters
Thomas T. Stallkamp Lead Independent Director
Age: 70
Bio & Compensation  - Reuters